17 alpha-hydroxyprogesterone caproate has been researched along with Recrudescence in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.11) | 29.6817 |
| 2010's | 30 (81.08) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Gandell, DL; Gudeman, JL; Randell, MD | 1 |
| Leveno, KJ; McIntire, DD; Nelson, DB | 1 |
| Eke, AC; Hesson, A; Oler, E | 1 |
| Dotters-Katz, SK; Goodnight, WH; Manuck, TA; Ning, A; Vladutiu, CJ | 1 |
| Manuck, TA | 1 |
| Fry, RC; Manuck, TA; Martin, EM; Smeester, L; Smith, C; Tomlinson, MS; Varner, MW | 1 |
| Caritis, SN; Hauspurg, A; Lemon, LS; Serra, AE; Sharma, S; Venkataramanan, R | 1 |
| Chauhan, SP; Easter, SR; Little, SE; Mendez-Figueroa, H; Robinson, JN | 1 |
| Bagga, R; Bansal, P; Kalra, J; Kumar, P; Shambhavi, S | 1 |
| Bofill, JA; Collier, CH; Morrison, JC; Pearson, M; Shwayder, JM | 1 |
| Jackson, J; Leziak, K; Miller, ES; Yee, LM | 1 |
| Kalata, M; Swarr, V; Teter, K; Wagner, L; Witzeman, K | 1 |
| Cahill, AG; Carter, EB; Macones, GA; Olsen, MA; Stout, MJ; Tuuli, MG | 1 |
| Caritis, SN; Carpenter, MW; Grobman, WA; Harper, M; Iams, JD; Klebanoff, MA; Mercer, BM; Ramin, S; Rouse, DJ; Sciscione, A; Sorokin, Y; Thom, E; Thorp, JM; Varner, MW; Venkataramanan, R; Wapner, RJ | 1 |
| Berghella, V; Caughey, AB; Iams, JD; Schoen, CN; Tabbah, S | 1 |
| Block-Abraham, D; Gee, RE; Orsulak, MK | 1 |
| Co, AL; Hade, EM; Iams, JD; Walker, HC | 1 |
| Allshouse, AA; Carey, JC; Heyborne, KD | 1 |
| Andrews, W; Biggio, J; Bukowski, R; Esplin, MS; Huang, H; Ilekis, J; Manuck, TA; Parry, S; Reddy, UM; Saade, G; Sadovsky, Y; Varner, MW; Zhang, H | 1 |
| Goodnight, W | 1 |
| Manuck, T; Menard, MK; Ollendorff, A; Stringer, EM; Stringer, JS; Verbiest, S; Vladutiu, CJ | 1 |
| Caritis, SN; Feghali, MN; Grobman, WA; Rouse, DJ | 1 |
| Esplin, MS; Fry, RC; Manuck, TA; Stoddard, GJ; Varner, MW | 1 |
| Batra, P; Menard, MK; Stringer, EM; Stringer, JSA; Vladutiu, CJ | 1 |
| Haidar, ZA; Hosseini Nasab, S; Moussa, HN; Sibai, BM | 1 |
| Andrews, W; Biggio, J; Bukowski, R; Esplin, MS; Huang, H; Ilekis, J; Jorde, LB; Manuck, TA; Parry, S; Reddy, UM; Saade, G; Sadovsky, Y; Varner, MW; Watkins, WS; Yandell, M; Zhan, H | 1 |
| Gard, J; Leveno, KJ; McDonald, J; McIntire, DD; Nelson, DB; Turrichi, P | 1 |
| Anderson, GD; Caritis, SN; Carpenter, MW; Harper, M; Iams, JD; Klebanoff, MA; Mercer, BM; Peaceman, AM; Ramin, SM; Rouse, DJ; Sciscione, A; Sorokin, Y; Thom, E; Thorp, J; Varner, MW; Wapner, RJ | 1 |
| Hall, NR | 1 |
| Klinger, G; Merlob, P; Stahl, B | 1 |
| Fox, NS; Peress, D; Rebarber, A; Romero, J; Saltzman, DH; Schwartz, R | 1 |
| Boyle, A; Driggers, RW; Feghali, M; Istwan, N; Rhea, D; Timofeev, J | 1 |
| Caritis, SN; Carpenter, M; Conway, D; Dombrowski, MP; Gabbe, S; Iams, JD; Klebanoff, M; Leindecker, S; Leveno, KJ; Meis, PJ; Mercer, B; Miodovnik, M; Moawad, AH; Northen, A; O'Sullivan, MJ; Peaceman, AM; Ramin, SM; Sibai, BM; Thorp, JM; Varner, MW; Wapner, RJ | 1 |
| Barton, JR; How, HY; Istwan, NB; Rhea, DJ; Stanziano, GJ | 1 |
| Istwan, N; Newman, R; Rhea, D; Rittenberg, C; Stanziano, G; Sullivan, S | 1 |
6 review(s) available for 17 alpha-hydroxyprogesterone caproate and Recrudescence
| Article | Year |
|---|---|
Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic; Recurrence | 2017 |
17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Evidence-Based Medicine; Female; Gestational Age; Humans; Hydroxyprogesterones; Obstetrics; Pregnancy; Premature Birth; Progestins; Recurrence; Risk Assessment; Risk Factors; United States | 2017 |
Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Recurrence; United States | 2016 |
What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Length Measurement; Cervix Uteri; Estrogen Antagonists; Evidence-Based Medicine; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2016 |
What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy Complications; Premature Birth; Progesterone; Progestins; Recurrence; Treatment Outcome | 2011 |
17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abnormalities, Drug-Induced; Animals; Cost Savings; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Evidence-Based Medicine; Female; Gestational Age; Humans; Hydroxyprogesterones; Injections; Pregnancy; Premature Birth; Recurrence; Risk Assessment; Risk Factors | 2012 |
8 trial(s) available for 17 alpha-hydroxyprogesterone caproate and Recrudescence
| Article | Year |
|---|---|
Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Female; Gestational Age; Humans; Logistic Models; Obesity; Pregnancy; Premature Birth; Progestins; Recurrence; Young Adult | 2018 |
Obstetric History and Likelihood of Preterm Birth of Twins.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Estrogen Antagonists; Female; Gestational Age; Humans; Infant, Newborn; Logistic Models; Pregnancy; Pregnancy Outcome; Pregnancy, Twin; Premature Birth; Recurrence; Risk Assessment; Risk Factors; Treatment Failure; United States; Young Adult | 2018 |
A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Drug Administration Schedule; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Progesterone; Progestins; Recurrence; Secondary Prevention; Treatment Outcome | 2018 |
Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Fatty Acids, Omega-3; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Recurrence | 2014 |
Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Female; Gestational Age; Humans; Hydroxyprogesterones; Obesity; Pregnancy; Premature Birth; Progesterone Congeners; Recurrence | 2015 |
Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Decision Support Techniques; Drug Administration Schedule; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Logistic Models; Male; Pregnancy; Premature Birth; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Treatment Failure | 2016 |
Effect of partial compliance on the prevention of recurrent preterm birth in women receiving weekly 17 alpha-hydroxyprogesterone caproate injections.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Medication Adherence; Pregnancy; Premature Birth; Recurrence; Treatment Outcome; Young Adult | 2017 |
Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Dietary Supplements; Double-Blind Method; Fatty Acids, Omega-3; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Pregnancy; Premature Birth; Progesterone Congeners; Recurrence | 2010 |
23 other study(ies) available for 17 alpha-hydroxyprogesterone caproate and Recrudescence
| Article | Year |
|---|---|
SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Pregnancy; Premature Birth; Progestins; Recurrence | 2020 |
FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Compounding; Drug Labeling; Female; Humans; Infant, Newborn; Pharmaceutical Services; Pregnancy; Premature Birth; Recurrence; United States; United States Food and Drug Administration | 2020 |
A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug and Narcotic Control; Drug Approval; Evidence-Based Medicine; Female; Humans; Observational Studies as Topic; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Recurrence; United States; United States Food and Drug Administration | 2021 |
Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Cohort Studies; Enterocolitis, Necrotizing; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant; Infant Mortality; Leukomalacia, Periventricular; Male; North Carolina; Pregnancy; Premature Birth; Progestins; Recurrence; Retrospective Studies | 2017 |
Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Case-Control Studies; CpG Islands; Epigenesis, Genetic; Estrogen Antagonists; Female; Gene Expression; Gestational Age; Humans; Infant, Newborn; Methylation; Nitric Oxide; Pregnancy; Premature Birth; Prospective Studies; Recurrence; Risk Factors; Signal Transduction | 2018 |
Reducing Barriers to 17-Hydroxprogestrone Caproate (17P) Injections to Prevent Recurrent Preterm Birth in Mississippi.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Education, Medical; Female; Health Services Accessibility; Humans; Hydroxyprogesterones; Mississippi; Pregnancy; Premature Birth; Progestins; Recurrence | 2016 |
Barriers and Facilitators to Recurrent Preterm Birth Prevention among Low-Income Women: A Qualitative Study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Attitude to Health; Female; Health Status Disparities; Humans; Injections, Intramuscular; Patient Satisfaction; Physician-Patient Relations; Poverty; Pregnancy; Premature Birth; Recurrence; Risk Factors; Secondary Prevention | 2019 |
Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Recurrence | 2021 |
Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Drug Administration Schedule; Estrogen Antagonists; Female; Gestational Age; Humans; Medication Adherence; Middle Aged; Obstetric Labor, Premature; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Premature Birth; Recurrence; Retrospective Studies; Young Adult | 2019 |
Why the United States preterm birth rate is declining.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adolescent; Adult; Cerclage, Cervical; Cervical Length Measurement; Evidence-Based Medicine; Female; Humans; Hydroxyprogesterones; Practice Guidelines as Topic; Pregnancy; Pregnancy in Adolescence; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins; Recurrence; Smoke-Free Policy; United States; Young Adult | 2015 |
17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Drug Administration Schedule; Female; Health Services Accessibility; Humans; Hydroxyprogesterones; Infant, Newborn; Insurance Coverage; Louisiana; Medicaid; Patient Protection and Affordable Care Act; Pregnancy; Premature Birth; Prenatal Care; Recurrence; Reimbursement, Incentive; United States | 2015 |
Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxyprogesterones; Obesity; Overweight; Pregnancy; Pregnancy Complications; Premature Birth; Progestins; Recurrence; Retrospective Studies; Young Adult | 2015 |
Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abruptio Placentae; Adult; Estrogen Antagonists; Female; Gestational Age; Humans; Hydroxyprogesterones; Longitudinal Studies; Pregnancy; Pregnancy, High-Risk; Premature Birth; Prospective Studies; Recurrence; Risk Factors; Treatment Failure; Uterine Hemorrhage; Young Adult | 2016 |
17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; North Carolina; Pregnancy; Premature Birth; Recurrence; Reproductive Control Agents; Retrospective Studies; Young Adult | 2016 |
Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Estrogen Antagonists; Female; Health Services Accessibility; Humans; Hydroxyprogesterones; Medication Adherence; Patient Selection; Pregnancy; Premature Birth; Prenatal Care; Recurrence; Secondary Prevention | 2016 |
The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Prenatal Care; Progestins; Recurrence; Risk Factors; Secondary Prevention | 2017 |
Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Analysis of Variance; Case-Control Studies; Exome Sequencing; Female; Gestational Age; Humans; Pharmacogenetics; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Recurrence; United States | 2018 |
17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cohort Studies; Diabetes, Gestational; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins; Prospective Studies; Recurrence; Treatment Outcome | 2017 |
The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Biomarkers; Cervical Length Measurement; Cohort Studies; Decision Support Techniques; Female; Fibronectins; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins; Recurrence; Regression Analysis; Retrospective Studies; Sensitivity and Specificity | 2012 |
Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Obesity; Pregnancy; Pregnancy Complications; Premature Birth; Progesterone Congeners; Recurrence; Retrospective Studies; Young Adult | 2013 |
Does progesterone treatment influence risk factors for recurrent preterm delivery?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Multivariate Analysis; Obstetric Labor, Premature; Pregnancy; Progestins; Recurrence; Risk Factors | 2005 |
Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Premature Birth; Recurrence; Retrospective Studies; Tocolytic Agents; Treatment Outcome | 2007 |
Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Outcome; Premature Birth; Recurrence; Residence Characteristics; Retrospective Studies; Tocolytic Agents | 2007 |